Selected article for: "chinese case and Hubei province"

Author: Campanati, A.; Brisigotti, V.; Diotallevi, F.; D’Agostino, G.M.; Paolinelli, M.; Radi, G.; Rizzetto, G.; Sapigni, C.; Tagliati, C.; Offidani, A.
Title: Active implications for dermatologists in “SARS‐CoV‐2 era”: Personal experience and review of literature
  • Cord-id: xyk2p92b
  • Document date: 2020_5_19
  • ID: xyk2p92b
    Snippet: On December 31, 2019, from the Chinese city of Wuhan, Hubei, comes the first case of "atypical ARDS/ interstitial pneumonia". On February 11, 2020 the WHO officially announced the name of the emergent disease associated with new coronavirus identified as SARS‐CoV‐2 (Severe Acute Respiratory Syndrome Coronavirus ‐2): COVID‐19 (Coronavirus Disease 2019) (1). On February 13, 72000 cases have been officially recorded in China, among which 15000 were registered in Hubei province only, with 24
    Document: On December 31, 2019, from the Chinese city of Wuhan, Hubei, comes the first case of "atypical ARDS/ interstitial pneumonia". On February 11, 2020 the WHO officially announced the name of the emergent disease associated with new coronavirus identified as SARS‐CoV‐2 (Severe Acute Respiratory Syndrome Coronavirus ‐2): COVID‐19 (Coronavirus Disease 2019) (1). On February 13, 72000 cases have been officially recorded in China, among which 15000 were registered in Hubei province only, with 242 deaths in a single day. After that, Chinese republic has ordered drastic containment measures for fighting SARS‐CoV‐2 virus spreading (1).

    Search related documents: